当前位置: 首页 >> 检索结果
81. Nailfold capillaroscopy improves cardiovascular risk stratification in SSc: an adjustment of the SCORE2 algorithm.
作者: Carlos Valera-Ribera.;Juan José Alegre-Sancho.;Miguel Ángel González-Gay.;Joaquín Lacasa-Molina.;Alida Taberner-Cortés.;Montserrat Robustillo-Villarino.;Javier Narváez.
来源: Rheumatology (Oxford). 2026年65卷3期
SSc is characterized by micro- and macrovascular damage, increasing cardiovascular (CV) risk. The SCORE2 algorithm underestimates CV risk in systemic autoimmune diseases. Nailfold capillaroscopy (NFC) is used to assess SSc-related microvascular damage. We aimed to evaluate whether incorporating NFC findings into SCORE2/SCORE2-OP improves CV risk stratification in SSc.
82. Acute myocarditis after switching between two adalimumab biosimilars.
作者: Thomas Subervie.;François Sauer.;Jean-Jacques Von Hunolstein.;Eden Sebbag.;Etienne Dahan.;Wilhelm Storck.;Jacques Eric Gottenberg.;Jean Sibilia.;Marc Scherlinger.
来源: Rheumatology (Oxford). 2026年65卷3期 83. Segmental spinal damage predicts mobility restriction and functional decline in radiographic axial spondyloarthritis: a longitudinal study.
作者: Ismail Sari.;Seunghun Lee.;Sindhu R Johnson.;Robert D Inman.;Nigil Haroon.
来源: Rheumatology (Oxford). 2026年
To quantify the longitudinal association between radiographic spinal damage and spinal mobility and physical function in radiographic axial spondyloarthritis (r-axSpA) using discovertebral unit (DVU)-level analyses.
86. Anti CD19 targeting CAR T cell therapy in ANCA-associated vasculitis.
作者: Luisa Schneider.;Ann-Christin Pecher.;Luca Hensen.;Patrick Krumm.;Rebekka Schairer.;Kristina Reuß.;Wolfgang Bethge.;Claudia Lengerke.;Joerg Henes.
来源: Rheumatology (Oxford). 2026年65卷3期
To present a successful case study of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in a patient with relapsing granulomatosis with polyangiitis (GPA).
88. Vaccination rates in rheumatic diseases: a cross-sectional register study on the role of patient beliefs and physician engagement.
作者: Samia Mehouachi.;Denis Mongin.;Gilles Eperon.;Delphine S Courvoisier.;Kim Lauper.
来源: Rheumatology (Oxford). 2026年
To evaluate the vaccination attitude and behaviour of patients with autoimmune inflammatory rheumatic diseases (AIIRD), and identify factors associated with vaccination status, utilising data from a national register.
89. B-cell monitoring predicts infection risk in childhood systemic lupus erythematosus patients on belimumab.
作者: Jingxiao Guo.;Yanjun Yang.;Lanlan Ge.;Peitong Han.;Fujuan Liu.;Meina Yin.
来源: Rheumatology (Oxford). 2026年
Belimumab improves outcomes in childhood-onset systemic lupus erythematosus (cSLE) but raises infection risks due to B cell modulation. We aimed to evaluate dynamic B cell and immunoglobulin G (IgG) monitoring for predicting infection risk.
91. Light-chain-restricted Russell body sialadenitis affecting the lower lip: an immunohistochemical study.
作者: Heitor Albergoni Silveira.;Gabriel Enrique Tantalean Laor.;Mariângela Ottoboni Brunaldi.;Eduardo Melani Rocha.;Fernando Chahud.;Jorge Esquiche León.
来源: Rheumatology (Oxford). 2026年 92. Time and patient journey to axial spondyloarthritis diagnosis: a retrospective study in French primary care.
作者: Clément Prati.;Arnaud Constantin.;Emmanuelle Dernis.;Jacques Eric Gottenberg.;Marc Rozenblat.;Elise Arnee.;Marie Ducros.;Cheikh Tamberou.;Anneleen Vyncke.;Julie Gandrup Horan.
来源: Rheumatology (Oxford). 2026年65卷3期
Axial spondyloarthritis (axSpA) diagnoses are often delayed, which is associated with poorer patient outcomes. To improve understanding of diagnostic delay in France, we describe the time and patient journey to axSpA diagnosis in primary care.
94. miR-23b-3p deficiency exacerbates immune dysregulation in immunoglobulin A vasculitis by enhancing TLR4-mediated dendritic cell activation.
作者: Yu Shan.;Xianxian Jia.;Yanan Ma.;Gang Luo.;Jingyi Qiao.;Zhenshi Li.;Seunghyun Lee.;Jieqing Zhou.;Liang Zhang.;Xiaoxue Ma.
来源: Rheumatology (Oxford). 2026年
MicroRNAs (miRNAs) play critical roles in regulating immune cell differentiation and maintaining innate and adaptive immune homeostasis. The aim of this study was to determine the mechanisms by which miR-23b-3p modulates crosstalk between innate and adaptive immunity in immunoglobulin A (IgA) vasculitis (IgAV) and to evaluate its therapeutic potential.
98. Renal outcomes in ANCA-associated vasculitis without clinically apparent kidney involvement: a multicentre REVEAL cohort study.
作者: Tomoki Taniguchi.;Ryosuke Hiwa.;Shingo Iwasaka.;Mikihito Shoji.;Atsushi Manabe.;Keiichiro Kadoba.;Tsuneyasu Yoshida.;Ryosuke Tsuge.;Shogo Matsuda.;Takuya Kotani.;Ayana Okazaki.;Yuichi Masuda.;Muneyuki Hatta.;Mayu Shiomi.;Naoko Ito.;Youhei Fujiki.;Hirofumi Miyake.;Shuji Sumitomo.;Hideki Oka.;Ryu Watanabe.;Motomu Hashimoto.;Akio Morinobu.
来源: Rheumatology (Oxford). 2026年65卷3期
Most studies on renal outcomes in ANCA-associated vasculitis (AAV) focus on GN; however, the prognosis of patients without clinically apparent kidney involvement is understudied. We aimed to characterize kidney prognosis in this overlooked subgroup.
99. Cardiovascular risk scores, non-invasive vascular measures and myositis damage index reveal increased cardiovascular risk in idiopathic inflammatory myopathies: a case-control study.
作者: Gabriela Paola Garcia-Ordoñez.;Carlos Gerardo Ramos-Becerra.;Fernanda-Isadora Corona-Meraz.;Mario Salazar-Paramo.;Felipe Perez-Vazquez.;Edgar-Federico Quirarte-Tovar.;Christian Juarez-Gomez.;Andrea Aguilar-Vazquez.;Monica Vazquez-Del Mercado.
来源: BMC Rheumatol. 2026年 100. Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.
作者: Athimalaipet V Ramanan.;Nicolino Ruperto.;Ivan Foeldvari.;Gabriel Vega-Cornejo.;Stuart Keller.;Rona Wang.;Joana Araújo.;Priyanka Sen.;Ketan Marulkar.;James Tseng.;Celine Pitou.;Pierre Quartier.
来源: Lancet Rheumatol. 2026年
Juvenile psoriatic arthritis and enthesitis-related arthritis are two categories of juvenile idiopathic arthritis (JIA). Despite available treatments including non-steroidal anti-inflammatory drugs, glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), and biological DMARDs, a substantial proportion of people do not adequately respond to treatment or do not have long-lasting clinical remission. The aim of this trial was to show the efficacy and safety of ixekizumab in children with active enthesitis-related arthritis and juvenile psoriatic arthritis.
|